  |
22 June 2006 |
In research presented at the 55th Annual Meeting of the
American Society of Tropical Medicine and Hygiene (ASTMH), Médecins
Sans Frontières (MSF) and its research affiliate, Epicentre, showed
how rapid, mass vaccinations can reduce the toll inflicted by measles
epidemics in Africa. In light of these and other findings, MSF feels
there is enough evidence for the WHO to revise its current policy recommendations,
which doubts the effectiveness of mass immunization once an epidemic
has started, stating that such campaigns would be undertaken too late
to have any meaningful impact.
Following MSF emergency interventions in Niger, Chad, Nigeria, and the
Democratic Republic of Congo (DRC), Epicentre found that early intervention
can lead to a high proportion of averted cases. Retrospective mortality
surveys also showed that measles epidemics last longer than previously
thought, allowing enough time to intervene and carry out emergency immunization
programs. One outbreak in Kinshasa, DRC, lasted more than 40 weeks during
2002 and 2003.
“We know we have time to respond during measles epidemics, and
the vaccine is effective just a few days after vaccination,” said
Rebecca Grais, an epidemiologist who helped lead the study. “Sadly,
the fact that the WHO does not promote vaccination campaigns during an
epidemic only hinders an effective emergency response.”
In Ndjamena, Chad in 2005, MSF proposed a mass vaccination campaign six
weeks and then again 13 weeks into an outbreak, but was refused both
times. MSF conducted the campaign nineteen weeks after the epidemic began,
and subsequently helped raise vaccination coverage in the area from 30%
to 85% in a matter of weeks.
In recent years, measles deaths have declined substantially in Africa
but recurrent, cyclical outbreaks occur in many countries – often
after 1-3 years of low incidence – and measles remains a major
cause of death for children in Africa.
“While laudable progress has been made in reducing measles deaths,
the toll from measles is still unacceptably high,” said Philippe
Guerin, deputy director of Epicentre. “We are talking about a vaccine
that costs 30 cents a dose for a completely preventable disease. Improvements
should not overshadow the intensive efforts and funding mechanisms needed,
especially during outbreaks.”
For more information, please contact James Nichols 0407 525
700 or 02 8570 2610
» See press release archive
|
 |
|